Stryker Corporation (NYSE:SYK) had its target price lifted by Stifel Nicolaus from $158.00 to $168.00 in a report published on Friday, October 27th. Stifel Nicolaus currently has a buy rating on the medical technology company’s stock.
SYK has been the subject of a number of other research reports. SunTrust Banks, Inc. restated a buy rating and issued a $161.00 target price on shares of Stryker Corporation in a research report on Monday, October 2nd. BidaskClub downgraded Stryker Corporation from a buy rating to a hold rating in a research report on Monday, July 31st. Zacks Investment Research downgraded Stryker Corporation from a hold rating to a sell rating in a research report on Monday, October 16th. Canaccord Genuity reaffirmed a buy rating and issued a $155.00 price target (down from $158.00) on shares of Stryker Corporation in a research note on Thursday, August 24th. Finally, Argus reaffirmed a buy rating and issued a $160.00 price target on shares of Stryker Corporation in a research note on Tuesday, August 29th. Two equities research analysts have rated the stock with a sell rating, ten have given a hold rating and twelve have assigned a buy rating to the stock. The company currently has an average rating of Hold and an average price target of $151.52.
Shares of Stryker Corporation (SYK) traded down $2.14 on Friday, hitting $154.48. The stock had a trading volume of 1,267,200 shares, compared to its average volume of 1,183,556. The company has a market cap of $58,613.09, a P/E ratio of 24.82, a PEG ratio of 2.47 and a beta of 0.79. The company has a current ratio of 2.37, a quick ratio of 1.61 and a debt-to-equity ratio of 0.63. Stryker Corporation has a 12-month low of $106.48 and a 12-month high of $160.62.
Stryker Corporation (NYSE:SYK) last issued its quarterly earnings results on Thursday, October 26th. The medical technology company reported $1.52 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.50 by $0.02. The firm had revenue of $3.01 billion during the quarter, compared to the consensus estimate of $2.97 billion. Stryker Corporation had a return on equity of 24.11% and a net margin of 14.67%. The company’s revenue for the quarter was up 6.1% on a year-over-year basis. During the same quarter last year, the company posted $1.39 EPS. equities research analysts expect that Stryker Corporation will post 6.47 EPS for the current year.
TRADEMARK VIOLATION WARNING: This article was originally reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this article on another website, it was stolen and republished in violation of U.S. & international trademark and copyright laws. The correct version of this article can be accessed at https://www.dispatchtribunal.com/2017/11/12/stryker-corporation-syk-pt-raised-to-168-00-at-stifel-nicolaus.html.
In related news, insider Lonny J. Carpenter sold 5,000 shares of the company’s stock in a transaction on Friday, November 3rd. The stock was sold at an average price of $155.34, for a total transaction of $776,700.00. Following the completion of the sale, the insider now owns 83,207 shares in the company, valued at $12,925,375.38. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Corporate insiders own 7.40% of the company’s stock.
Large investors have recently bought and sold shares of the company. Acrospire Investment Management LLC bought a new stake in shares of Stryker Corporation in the 2nd quarter valued at approximately $111,000. Motco lifted its stake in shares of Stryker Corporation by 50.7% in the 2nd quarter. Motco now owns 826 shares of the medical technology company’s stock valued at $115,000 after purchasing an additional 278 shares during the last quarter. Bollard Group LLC lifted its stake in shares of Stryker Corporation by 0.4% in the 2nd quarter. Bollard Group LLC now owns 832 shares of the medical technology company’s stock valued at $115,000 after purchasing an additional 3 shares during the last quarter. Bruderman Asset Management LLC bought a new stake in shares of Stryker Corporation in the 2nd quarter valued at approximately $150,000. Finally, James Investment Research Inc. bought a new stake in shares of Stryker Corporation in the 2nd quarter valued at approximately $155,000. 74.13% of the stock is owned by institutional investors and hedge funds.
About Stryker Corporation
Stryker Corporation is a medical technology company. The Company offers a range of medical technologies, including orthopedic, medical and surgical, and neurotechnology and spine products. The Company’s segments include Orthopaedics; MedSurg; Neurotechnology and Spine, and Corporate and Other. The Orthopaedics segment includes reconstructive (hip and knee) and trauma implant systems and other related products.
Receive News & Ratings for Stryker Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker Corporation and related companies with MarketBeat.com's FREE daily email newsletter.